GeneHealth - Your precision medicine

Tracheal Cancer

Disease Details

Family Health Simplified

Buy Membership

Description: Tracheal cancer is a rare malignancy that originates in the windpipe, obstructing airflow and causing symptoms such as coughing, difficulty breathing, and hoarseness.
Type: Tracheal cancer is primarily a type of carcinoma, with squamous cell carcinoma being the most common histological subtype. It is not typically associated with genetic transmission or inherited genetic mutations. Most cases are related to environmental risk factors, such as smoking and exposure to certain chemicals.
Signs And Symptoms: Early lung cancer often has no symptoms. When symptoms do arise they are often nonspecific respiratory problems – coughing, shortness of breath, or chest pain – that can differ from person to person. Those who experience coughing tend to report either a new cough, or an increase in the frequency or strength of a pre-existing cough. Around one in four cough up blood, ranging from small streaks in the sputum to large amounts. Around half of those diagnosed with lung cancer experience shortness of breath, while 25–50% experience a dull, persistent chest pain that remains in the same location over time. In addition to respiratory symptoms, some experience systemic symptoms including loss of appetite, weight loss, general weakness, fever, and night sweats.Some less common symptoms suggest tumors in particular locations. Tumors in the thorax can cause breathing problems by obstructing the trachea or disrupting the nerve to the diaphragm; difficulty swallowing by compressing the esophagus; hoarseness by disrupting the nerves of the larynx; and Horner's syndrome by disrupting the sympathetic nervous system. Horner's syndrome is also common in tumors at the top of the lung, known as Pancoast tumors, which also cause shoulder pain that radiates down the little-finger side of the arm as well as destruction of the topmost ribs. Swollen lymph nodes above the collarbone can indicate a tumor that has spread within the chest. Tumors obstructing bloodflow to the heart can cause superior vena cava syndrome (swelling of the upper body and shortness of breath), while tumors infiltrating the area around the heart can cause fluid buildup around the heart, arrythmia (irregular heartbeat), and heart failure.About one in three people diagnosed with lung cancer have symptoms caused by metastases in sites other than the lungs. Lung cancer can metastasize anywhere in the body, with different symptoms depending on the location. Brain metastases can cause headache, nausea, vomiting, seizures, and neurological deficits. Bone metastases can cause pain, bone fractures, and compression of the spinal cord. Metastasis into the bone marrow can deplete blood cells and cause leukoerythroblastosis (immature cells in the blood). Liver metastases can cause liver enlargement, pain in the right upper quadrant of the abdomen, fever, and weight loss.Lung tumors often cause the release of body-altering hormones, which cause unusual symptoms, called paraneoplastic syndromes. Inappropriate hormone release can cause dramatic shifts in concentrations of blood minerals. Most common is hypercalcemia (high blood calcium) caused by over-production of parathyroid hormone-related protein or parathyroid hormone. Hypercalcemia can manifest as nausea, vomiting, abdominal pain, constipation, increased thirst, frequent urination, and altered mental status. Those with lung cancer also commonly experience hypokalemia (low potassium) due to inappropriate secretion of adrenocorticotropic hormone, as well as hyponatremia (low sodium) due to overproduction of antidiuretic hormone or atrial natriuretic peptide. About one of three people with lung cancer develop nail clubbing, while up to one in ten experience hypertrophic pulmonary osteoarthropathy (nail clubbing, joint soreness, and skin thickening). A variety of autoimmune disorders can arise as paraneoplastic syndromes in those with lung cancer, including Lambert–Eaton myasthenic syndrome (which causes muscle weakness), sensory neuropathies, muscle inflammation, brain swelling, and autoimmune deterioration of cerebellum, limbic system, or brainstem. Up to one in twelve people with lung cancer have paraneoplastic blood clotting, including migratory venous thrombophlebitis, clots in the heart, and disseminated intravascular coagulation (clots throughout the body). Paraneoplastic syndromes involving the skin and kidneys are rare, each occurring in up to 1% of those with lung cancer.
Prognosis: Around 19% of people diagnosed with lung cancer survive five years from diagnosis, though prognosis varies based on the stage of the disease at diagnosis and the type of lung cancer. Prognosis is better for people with lung cancer diagnosed at an earlier stage; those diagnosed at the earliest TNM stage, IA1 (small tumor, no spread), have a two-year survival of 97% and five-year survival of 92%. Those diagnosed at the most-advanced stage, IVB, have a two-year survival of 10% and a five-year survival of 0%. Five-year survival is higher in women (22%) than men (16%). Women tend to be diagnosed with less-advanced disease, and have better outcomes than men diagnosed at the same stage. Average five-year survival also varies across the world, with particularly high five-year survival in Japan (33%), and five-year survival above 20% in 12 other countries: Mauritius, Canada, the US, China, South Korea, Taiwan, Israel, Latvia, Iceland, Sweden, Austria, and Switzerland.SCLC is particularly aggressive. 10–15% of people survive five years after a SCLC diagnosis. As with other types of lung cancer, the extent of disease at diagnosis also influences prognosis. The average person diagnosed with limited-stage SCLC survives 12–20 months from diagnosis; with extensive-stage SCLC around 12 months. While SCLC often responds initially to treatment, most people eventually relapse with chemotherapy-resistant cancer, surviving an average 3–4 months from the time of relapse. Those with limited stage SCLC that go into complete remission after chemotherapy and radiotherapy have a 50% chance of brain metastases developing within the next two years – a chance reduced by prophylactic cranial irradiation.Several other personal and disease factors are associated with improved outcomes. Those diagnosed at a younger age tend to have better outcomes. Those who smoke or experience weight loss as a symptom tend to have worse outcomes. Tumor mutations in KRAS are associated with reduced survival.
Onset: Tracheal cancer's onset is typically insidious, meaning it develops gradually and can go unnoticed in its early stages. Common early symptoms include persistent cough, difficulty breathing, and stridor (a high-pitched wheezing sound). Because these symptoms can be mistaken for other respiratory conditions, tracheal cancer is often diagnosed at a more advanced stage.
Prevalence: Tracheal cancer is very rare compared to other types of cancer. It accounts for less than 1% of all respiratory tract cancers. The exact prevalence is not well-documented due to its rarity.
Epidemiology: Worldwide, lung cancer is the most diagnosed type of cancer, and the leading cause of cancer death. In 2020, 2.2 million new cases were diagnosed, and 1.8 million people died from lung cancer, representing 18% of all cancer deaths. Lung cancer deaths are expected to rise globally to nearly 3 million annual deaths by 2035, due to high rates of tobacco use and aging populations. Lung cancer is rare among those younger than 40; after that, cancer rates increase with age, stabilizing around age 80. The median age of a person diagnosed with lung cancer is 70; the median age of death is 72.Lung cancer incidence varies by geography and sex, with the highest rates in Micronesia, Polynesia, Europe, Asia, and North America; and lowest rates in Africa and Central America. Globally, around 8% of men and 6% of women develop lung cancer in their lifetimes. The ratio of lung cancer cases in men to women varies considerably by geography, from as high as nearly 12:1 in Belarus, to 1:1 in Brazil, likely due to differences in smoking patterns.Lung cancer risk is influenced by environmental exposure, namely cigarette smoking, as well as occupational risks in mining, shipbuilding, petroleum refining, and occupations that involve asbestos exposure. People who have smoked cigarettes account for 85–90% of lung cancer cases, and 15% of smokers develop lung cancer. Non-smokers' risk of developing lung cancer is also influenced by tobacco smoking; secondhand smoke (that is, being around tobacco smoke) increases risk of developing lung cancer around 30%, with risk correlated to duration of exposure.
Intractability: Tracheal cancer can be challenging to treat due to its rarity, late diagnosis, and proximity to critical structures in the respiratory system. However, it is not considered universally intractable. Treatment options, including surgery, radiation therapy, and chemotherapy, can be effective, especially when the disease is detected early. Advanced stages may present more difficulties in management.
Disease Severity: Tracheal cancer, also known as tracheal carcinoma, is a rare but serious condition characterized by malignant tumors originating in the trachea.

### Disease Severity
The severity of tracheal cancer can vary based on factors such as the stage at diagnosis, the tumor's size and location, the cancer's spread (metastasis), and the patient's overall health. Early-stage tracheal cancer might be more localized and potentially treatable with a better prognosis, while advanced-stage cancer can be more challenging to treat and may have a poorer prognosis. Symptoms often include difficulty breathing, coughing (sometimes with blood), and wheezing, and they can escalate as the disease progresses.

### Nan
'Nan' relates to "not a number" or missing data in certain contexts, but in the context of tracheal cancer, this term doesn't apply directly. If you have more specific concerns or additional queries, please provide further details for a more targeted response.
Healthcare Professionals: Disease Ontology ID - DOID:11920
Pathophysiology: Tracheal cancer is a rare malignancy originating in the trachea, or windpipe. The pathophysiology typically involves the uncontrolled growth of malignant cells in the lining of the trachea. The two most common types of tracheal cancer are squamous cell carcinoma and adenoid cystic carcinoma:

1. **Squamous Cell Carcinoma**: This type often develops in the epithelial cells lining the trachea and is strongly associated with smoking. It usually presents as a locally advanced disease.

2. **Adenoid Cystic Carcinoma**: This type arises from the submucosal glands of the trachea and tends to grow more slowly than squamous cell carcinoma. It can spread along the trachea and invade surrounding tissues.

Tumor growth in the trachea can lead to obstruction of the airway, causing symptoms like coughing, difficulty breathing, wheezing, and recurrent respiratory infections. Metastasis to regional lymph nodes and distant organs can occur, complicating the disease course. Early diagnosis and treatment are crucial for managing tracheal cancer.
Carrier Status: Carrier status is not applicable to tracheal cancer.
Mechanism: Tracheal cancer is a rare malignancy that affects the trachea, or windpipe. The mechanisms and molecular aspects that drive this type of cancer can involve several factors:

### Mechanism:
1. **Carcinogenesis**: The development of tracheal cancer typically begins with genetic mutations in the tracheal epithelial cells. These mutations can be triggered by carcinogens such as tobacco smoke, industrial pollutants, or chronic inflammation due to infections.

2. **Tumor Growth**: The mutated cells start to proliferate uncontrollably, forming a tumor. Over time, the tumor can obstruct the trachea, causing symptoms like coughing, dyspnea (difficulty in breathing), and hemoptysis (coughing up blood).

### Molecular Mechanisms:
1. **Genetic Mutations**: Key genetic changes, including mutations in oncogenes (e.g., EGFR, KRAS) and tumor suppressor genes (e.g., TP53), play a crucial role. Mutation in TP53, for instance, can lead to loss of cell cycle control and apoptosis, facilitating unregulated cell growth.

2. **Epigenetic Modifications**: Changes in DNA methylation and histone modification can also contribute to the dysregulation of gene expression, which may aid the cancerous transformation of cells.

3. **Signal Transduction Pathways**: Abnormalities in various signaling pathways, such as the EGFR pathway, can promote cell proliferation, survival, angiogenesis, and metastasis. Overexpression or mutation of EGFR often results in increased signaling activity, leading to tumor growth.

4. **Angiogenesis**: The process of new blood vessel formation is critical for tumor growth and metastasis. Factors like VEGF (Vascular Endothelial Growth Factor) stimulate this process, providing the tumor with nutrients and oxygen.

Understanding these mechanisms helps in developing targeted therapies, such as tyrosine kinase inhibitors for EGFR mutations, which can improve treatment outcomes for patients with tracheal cancer.
Treatment: Treatment for lung cancer depends on the cancer's specific cell type, how far it has spread, and the person's health. Common treatments for early stage cancer includes surgical removal of the tumor, chemotherapy, and radiation therapy. For later-stage cancer, chemotherapy and radiation therapy are combined with newer targeted molecular therapies and immune checkpoint inhibitors. All lung cancer treatment regimens are combined with lifestyle changes and palliative care to improve quality of life.
Compassionate Use Treatment: Compassionate use treatment, also known as expanded access, refers to the use of investigational drugs outside of clinical trials for patients with serious or life-threatening conditions when no comparable or satisfactory alternative treatments are available. For tracheal cancer, compassionate use might include access to experimental drugs or treatments that are still under clinical investigation.

Off-label or experimental treatments for tracheal cancer may include:

1. **Targeted Therapy**: Drugs that target specific genetic mutations or protein expressions found in the cancer cells. Examples include tyrosine kinase inhibitors like erlotinib or crizotinib.

2. **Immunotherapy**: Treatment that uses the body's immune system to fight cancer. Checkpoint inhibitors such as pembrolizumab or nivolumab are sometimes used off-label for tracheal cancer.

3. **Photodynamic Therapy (PDT)**: A form of treatment that uses light-sensitive drugs and a light source to destroy cancer cells, occasionally experimented with in tracheal cancers.

4. **Gene Therapy**: Emerging treatments that involve modifying the genetic material within cells to fight or prevent disease. While still largely experimental, some studies are exploring this for various cancers including tracheal cancer.

5. **Chemotherapeutic Agents**: Some chemotherapy drugs approved for other cancers might be used off-label for tracheal cancer, depending on the specific circumstances and the oncologist’s discretion.

These treatments are typically pursued in specialized medical centers and often require thorough patient evaluation and regulatory approvals, given their experimental nature.
Lifestyle Recommendations: For tracheal cancer, the following lifestyle recommendations may be beneficial:

1. **Quit Smoking:** Smoking is a significant risk factor for tracheal cancer. Quitting smoking can reduce the risk and improve overall health.

2. **Healthy Diet:** A balanced diet rich in fruits, vegetables, and whole grains can support general health and may boost the immune system.

3. **Limit Alcohol Consumption:** Reducing alcohol intake can decrease the risk of developing various cancers, including tracheal cancer.

4. **Regular Exercise:** Engaging in regular physical activity can improve overall well-being and may reduce the risk of various cancers.

5. **Avoid Occupational Hazards:** If your job exposes you to harmful substances such as chemicals, dust, or fumes, use protective equipment and follow safety guidelines to minimize risk.

6. **Regular Check-ups:** Routine medical check-ups can help in early detection and management of potential health issues, including tracheal cancer.

7. **Manage Chronic Conditions:** Proper management of chronic respiratory conditions, such as asthma or chronic obstructive pulmonary disease (COPD), may be beneficial.

Making these lifestyle changes can help support overall health and potentially reduce the risk of developing tracheal cancer.
Medication: Tracheal cancer is relatively rare and its treatment typically involves a combination of therapies. Medications specifically prescribed for tracheal cancer may include chemotherapy drugs such as cisplatin, carboplatin, and etoposide, which work to destroy cancer cells. Additionally, targeted therapies and immunotherapy might be considered, depending on the molecular characteristics of the cancer. It's important to consult an oncologist for a treatment plan tailored to the individual patient's condition.
Repurposable Drugs: For tracheal cancer, repurposable drugs refer to medications originally developed and approved for other conditions that have shown potential in treating this rare type of cancer. Some examples include:

1. **Metformin**: Typically used for type 2 diabetes, has shown anti-cancer properties in various studies.
2. **Statins**: Commonly prescribed for lowering cholesterol, some studies indicate they may inhibit cancer cell growth.
3. **Aspirin**: An anti-inflammatory drug that has demonstrated potential in reducing cancer risk and progression.

These drugs are still under investigation for their efficacy and safety in treating tracheal cancer specifically. Consultation with an oncologist is essential before considering any repurposed drug treatments.
Metabolites: For tracheal cancer, specific metabolites are not distinctly identified as biomarkers. Metabolomics in cancer research is still evolving, and currently, specific metabolite profiles for tracheal cancer are not well-established or widely recognized. General cancer metabolomics focus on altered energy metabolism, like increased glucose uptake and lactate production, but specifics for tracheal cancer require further research.
Nutraceuticals: There is limited evidence supporting the use of nutraceuticals for tracheal cancer specifically. While some nutraceuticals have shown potential in general cancer prevention or support, they should not replace conventional treatments. Nutraceuticals such as antioxidants (e.g., vitamins C and E), omega-3 fatty acids, and certain polyphenols might support overall health but their specific effects on tracheal cancer need more research. Always consult a healthcare provider before using any supplement.
Peptides: Peptide-based therapies and nanoparticles (nanomedicine) represent emerging strategies in the treatment of tracheal cancer. Peptides can be designed to target specific cancer cells, potentially improving the efficacy and specificity of treatments while minimizing side effects. Nanoparticles can serve as delivery systems for these peptides or other therapeutic agents, allowing for targeted delivery directly to the tumor site, enhancing drug concentration at the tumor while reducing systemic toxicity. Both approaches are under active research and show promise for improving outcomes in tracheal cancer therapy.